Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. (IKT) SEC Filings & 10-K Annual Reports
SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.
SEC EDGAR · data.sec.gov · CIK 0001750149 · IKT · NASDAQ · as of Jun 9, 2026
Filing snapshot
Source: SEC EDGAR (data.sec.gov) · CIK 0001750149 · Updated hourly · Not investment advice
Latest Annual Report
Latest Key Filings
Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.
SEC Filing History
About SEC Filings & 10-K Annual Reports
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) has submitted 341 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001750149, all filings are publicly accessible via the EDGAR database at no cost.
The annual 10-K report is Inhibikase Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Inhibikase Therapeutics, Inc. 10-K was filed on 2026-03-26 for fiscal year ending 2026. Historical IKT 10-K annual reports are available from 2018 through 2026.
Investors researching Inhibikase Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.
Frequently Asked Questions
IKT SEC Filings · 8 questionsInhibikase Therapeutics, Inc. (IKT) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 341 filings and access original documents at no cost. Inhibikase Therapeutics, Inc.'s CIK is 0001750149.